Modern Standards: Your Treatment Options

The way doctors treat Restless Legs Syndrome (RLS) has undergone a dramatic transformation. In 2024, the American Academy of Sleep Medicine (AASM) released updated clinical practice guidelines that fundamentally change the “first-line” approach for patients ^[1]. If you were diagnosed years ago, your current treatment plan may no longer align with these modern standards of care.

The Major Shift: Gabapentinoids First

For decades, medications that mimic dopamine (called dopamine agonists, such as pramipexole or ropinirole) were the go-to treatment. However, the 2024 guidelines now prefer gabapentinoids (also known as alpha-2-delta ligands) as the primary choice for most patients ^[1][2]. This class includes:

• Gabapentin
• Pregabalin
• Gabapentin enacarbil

These medications are now preferred because they effectively calm the overactive sensory signals in the nervous system without the high long-term risks associated with dopamine-based drugs ^[2][3].

Safety and Side Effects: While significantly safer than dopamine agonists in terms of long-term disease worsening, gabapentinoids are not without side effects. Patients must be aware of potential issues like dizziness, daytime somnolence (sleepiness), weight gain, and “brain fog” ^[2]. Importantly, they can cause respiratory depression if combined with other central nervous system depressants. Like dopamine drugs, they also require a careful, slow taper if you decide to stop taking them to avoid withdrawal symptoms.

Why Dopamine Agonists are No Longer First-Line

While dopamine agonists often work very well at first, they carry a severe risk called augmentation ^[4][2]. Augmentation is a treatment-induced worsening of the condition where symptoms begin earlier in the day, the intensity becomes much stronger, and the restlessness spreads to the arms or trunk ^[4][5]. You can learn more about this dangerous cycle in When the Medicine Makes It Worse: Augmentation.

Iron: The Foundation of Treatment

Before starting any long-term medication, the 2024 guidelines emphasize maximizing your body’s iron stores ^[6].

• Oral or IV Iron: Recommended if your ferritin is ≤ 75 ng/mL or your transferrin saturation (TSAT) is < 20% ^[1].
• Intravenous (IV) Iron Only: If your ferritin is between 75 and 100 ng/mL, the guidelines specifically suggest IV iron (such as ferric carboxymaltose) ^[1]. At these levels, oral pills are often not potent enough to cross the blood-brain barrier. Be prepared that while IV iron may be clinically recommended, getting insurance approval can sometimes be a hurdle, requiring you to advocate for yourself.

Options for Severe, Refractory RLS

If first-line treatments (iron and gabapentinoids) fail or cause intolerable side effects, the condition is considered refractory ^[2]. In these severe cases, low-dose opioids (such as oxycodone-naloxone) may be prescribed ^[7][8].

While the word “opioid” can be alarming, research shows that at the very low doses used for RLS (a small fraction of what is prescribed for pain management), these medications can provide long-term, stable relief without the high risks of addiction often associated with higher-dose prescribing ^[9][10]. Because they can affect breathing during sleep, your doctor will monitor you closely, often requiring a sleep study before starting therapy ^[8][11].

Managing RLS today is about more than just “stopping the movement”; it is about choosing the safest long-term path for your neurological health ^[1].